British Journal of Dermatology

Article	Citations
银屑病皮肤细胞中的小分子 RNA 促进炎症发生	230
Correction	180
P91: Cutaneous adverse events of immune check point inhibitors nivolumab, pembrolizumab and atezolizumab: a multicentric study	139
Adding up the desmosomal genes causing syndromes with hair and skin involvement: identification of TUFT1 by state-of-the-art whole-genome sequencing	118
Comparison of incidence, causes and prognosis of adult and paediatric epidermal necrolysis: a French population-based study	100
Atypical melanocytes of an atypical Spitz tumour observed with optical super-high magnification dermoscopy	100
How to score the impact of treatment on cutaneous neurofibromas in clinical trials	92
Delusional infestation – do not be scared!	85
The association of anxiety with granuloma annulare: a case–control study of the National Institutes of Health ‘All of Us’ research programme	85
O11 The human discs large protein (Dlg1) controls connexin 43 (Cx43) plasma membrane localization and gap junctional communication in keratinocytes	81
O06 Exploring host–microbiome–immune interactions using singular and multispecies inoculations in optimized 3D skin models	78
Interactive effect of genetic and environmental risk factors on psoriasis: current evidence and future directives	75
Editor's Choice – John Ingram – Sep 2023	75
一项在一家大型教学医院进行的 5 年皮肤附属器肿瘤研究, 对关联基因诊断提供了启示	74
对化疗所致脱发的更深入了解	69
P100: Efficacy of current treatments under study in patients with alopecia areata	68
BH13: Scarring alopecia affecting a congenital melanocytic naevus in a patient with frontal fibrosing alopecia	68
P15: Twenty years of the UK Dermatology Clinical Trials Network: past, present and future	66
CPC11: Bromoderma in a patient with chronic obstructive pulmonary disease	62
P57: New order: redesigning referral pathways to improve access for patients from dermatology outpatient waiting lists	59
H10: A Sweet diagnosis to make: the history of Robert Douglas Sweet and acute febrile neutrophilic dermatosis	58
BH09: Frontal fibrosing alopecia in men: is it any different?	58
开展健康宣传活动，禁售日光浴床，以减少皮肤癌: 合理利用医疗预算	58
Issue Information	57
P52: Opportunities for implementing a patient‐initiated follow‐up pathway in patients with psoriasis completing narrowband ultraviolet B phototherapy	57

DP27: Maculopapular cutaneous mastocytosis mimicking seborrhoeic folliculitis	56
Possible new oral treatment for hidradenitis suppurativa	56
P53: Office 365: Microsoft Lists as a tool for a secure online second‐line/systemic drug database	54
Higher proportion of cellulitis in severe lymphoedema	53
DP12: An 11‐year mystery	53
皮肤红斑狼疮治疗指南	53
Integrating artificial intelligence into skin cancer pathways: the opportunities and obstacles	50
Greater understanding about differences in the long-term course of eczema and their risk factors in children	49
520 - Evaluating the expression of OX40 and OX40 ligand in lesional skin versus non-lesional skin in volunteers with atopic dermatitis and in healthy control skin	48
Methotrexate and ciclosporin improve skin biomarkers in paediatric atopic dermatitis: results from the TREatment of severe Atopic eczema Trial	47
561 - Dupilumab treatment reduces signs in patients with atopic hand and foot dermatitis: results from a phase 3, randomized, double-blind, placebo-controlled trial	47
A current need for the use of improved and standardized outcome measures by clinical studies of pemphigus	45
A guide to using the core outcome set for eczema	45
Occupational skin cancer: measurements of ultraviolet radiation exposure bring knowledge for prevention	45
GD07: The use of the Dermatology Life Quality Index suite of patient‐reported outcome measures in neglected tropical diseases of the skin: a systematic review	44
Risankizumab versus apremilast in the era of skin clearance	43
BT25: Dermatology and the metaverse: what’s on the horizon?	43
Editor's Choice – John Ingram – December 2023	43
Corrigendum	43
‘Substantial clinical benefit’ and ‘substantial clinical worsening’ cutoff of Vitiligo Impact Scale (VIS)-22 change scores	43
Mosaic EGFR exon 20 in-frame insertion pathogenic variants are associated with papular epidermal naevus with ‘skyline’ basal cell layer (PENS)	43
Incidence, mortality and survival in people with Merkel cell carcinoma: a systematic review	42
O22 Unravelling the pathophysiology of KLICK syndrome to identify therapeutically targetable pathways	42
Dupilumab improves patient-reported symptoms and health-related quality of life in children aged 6–11 years with severe atopic dermatitis	41
Multicentre phase II trial of plasminogen activator inhibitor-1 inhibitor (TM5614) plus nivolumab in Japanese advanced melanoma patients: immune resistance remains one of the major efforts in melanoma	41
UK trends in work-related contact dermatitis caused by nickel, chromium and cobalt	40
PA12 Fats and figures: how abnormal lipids unravel the truth	39
BH09 Mycophenolate mofetil in the management of lichen planus pigmentosus in a woman with frontal fibrosing alopecia	39
H19 Not only a finder of ‘solutions’: Max Jessner, Holocaust survivor and discoverer of Jessner–Kanof lymphocytic infiltrate	38
H06 The changing face of skin disease in warfare: from World War I to modern times	38
H20 Sarcoptes scabiei: to solve the current crisis, hunt for clues in our past	38
BH13 Current wig prescribing practices and financial evaluation in a National Health Service foundation trust: lessons learnt and future challenges	38
Poster presentationsPA10 Hidradenitis suppurativa and trisomy 21: a case series	38
DS24 Is surgery the best management for keratoacanthoma centrifugum marginatum?	37
SG08 The phenotypic spectrum of MBTPS2 mutations: two illustrative cases	37
Poster presentationsBT15 Ethical implications of artificial intelligence in dermatology: use-case analysis of skin cancer diagnostic smartphone apps	37
DS23 Evaluation of American Joint Committee on Cancer and alternative tumour classification systems for primary penile squamous cell carcinoma	37
O05 Risk of keratinocyte carcinomas in patients with psoriasis treated with biologic therapy: analysis from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR),	36
The role of clinicians in dermatology industry innovation: a qualitative study	36
P093 Bespoke omalizumab prescribing in chronic spontaneous urticaria	36
Mainstreaming genetic testing in dermatology in the UK	36
Uncovering the genetic architecture of hidradenitis suppurativa	35
Navigating challenges in clinical trials for bullous pemphigoid and pemphigus: learnings from the clinical trial graveyard and an international expert survey	35
Avelumab plus cetuximab in advanced cutaneous squamous cell carcinoma: a strategy to overcome resistance to PD-1 blockade	35
Evaluating the role of histopathology in diagnosing pyoderma gangrenosum using Delphi and PARACELSUS criteria: a multicentre, retrospective cohort study	34
Correction to: Efficacy and safety of ciclosporin versus methotrexate in the treatment of severe atopic dermatitis in children and young people (TREAT): a multicentre parallel group assessor-blinded c	34
From connective tissue builders to cellular architects: the journey of the skin fibroblast	34
The Venous Garland of Sahli	34
Multi-Harmonic Imaging-Based Automated Recognition of Cutaneous T-Cell Lymphoma	34
Neutrophil infiltration in allergic contact dermatitis to nickel	34

Proliferative actinic keratoses are associated with adverse clinical outcomes relative to actinic keratoses without a proliferative growth pattern	34
Can the effects of the COVID-19 pandemic provide insights into the impact of melanoma underdiagnosis and delayed care?	33
Prurigo nodularis: disease burden, clinical features and approach to management	33
CD03 Contact sensitization to shellac: a possible marker of fragrance allergy	33
Real-world study of pegylated interferon α-2a to treat mycosis fungoides/Sézary syndrome using time to next treatment as a measure of clinical benefit: an EORTC CLTG study	33
Mechanistic in vivo studies of secondary skin-to-skin peanut allergen transfer to determine the impact of hand washing in reducing the risk of cutaneous sensitization	33
Newborn genome screening (the Generation Study): the advent of presymptomatic diagnosis for genodermatoses	33
010 Enhanced outcome prediction in cutaneous squamous cell carcinoma using deep-learning and computational histopathology (cSCCnet)	32
P13 A rare case of Sjögren syndrome in a White woman with Kikuchi–Fujimoto disease	32
730 - Patient opinions on healthcare provider interactions and current treatment satisfaction in adults with atopic dermatitis by race and ethnicity	31
P50 Exploring unmet needs and attitudes to skin self-examination in melanoma survivors: EUNASS study	31
PA37 A retrospective review of the impact of virtual reality headsets in paediatric skin surgery	31
SG10 (P058) The epidemiology of epidermolysis bullosa in England, 1997–2024: a retrospective national cohort study	31
CPC02 Delayed widespread lichenoid drug reaction with radioisotopic response in a patient treated with nivolumab	31
DP22 Cutaneous lymphoid hyperplasia: clinicopathological correlation and a therapeutic option	31
P74 Guselkumab clinical super-response is associated with faster normalization of blood and skin pathology: data from the Phase 3b GUIDE trial	30
P068 Oral tofacitinib in comparison with dexamethasone oral mini-pulse therapy for the treatment of active nonsegmental vitiligo: a randomized controlled trial	30
BH08 Unprovoked pulmonary emboli in a patient with alopecia areata treated with ritlecitinib: a case report	29
SG02 Transdermal testosterone improves lower-extremity ulceration in a young man with newly diagnosed Klinefelter syndrome (47 XXY)	29
P67 Overall lifetime risk for alopecia areata is 2.1% and is higher in women, non-White ethnic groups and the most deprived: a UK population-based cohort study	29
PA24 Abnormal interferon signature in a patient with chilblain lupus	29
BI26 Treatment-induced scleroderma in a patient with metastatic melanoma	28
677 - Establishing a patient-centered definition of atopic dermatitis flare: insights from a modified eDelphi study	28
335 Improvement in sleep quality, anxiety and depression in adults with moderate-to-severe atopic dermatitis with dupilumab treatment	28
603 - Ruxolitinib cream 1.5% twice daily for the treatment of extensive atopic dermatitis in children aged 2–11 years: 52 week results from a maximum-use trial	28
BH18 A rare case of nail sarcoidosis presenting as an ulcerated nail tumour in a Afro-Caribbean patient	28
DP21 Thymoma and the skin: manifestations of multiorgan autoimmunity	27
691 - Understanding patient and physician preferences when choosing between biologic and oral systemic treatment options for moderate-to-severe atopic dermatitis: a discrete choice experiment	27
705 - Patient preferences for atopic dermatitis treatment profiles: results from a discrete choice experiment	27
P19 The association between psoriatic disease severity and adherence to the Mediterranean diet: a systematic review of observational studies	27
P020 A rare phenomenon in a rare disease: reverse Koebner phenomenon in cutaneous Rosai–Dorfman disease	27
673 - Efficacy of nemolizumab in different subgroups of patients with prurigo nodularis in two randomized, placebo-controlled phase 3 trials	27
O02 Skin cancer service disparities across England: what data can tell us about skin cancer diagnosis, referral pathways and treatment received in different NHS trusts	27
643 - Effectiveness and safety of upadacitinib in adolescent and adult patients with atopic dermatitis: an analysis of short-term (week 8-20) data from a real-world multicenter retrospective review	27
P099 Spesolimab use in effective treatment of generalized pustular psoriasis: a case report	26
BH10 Nailing the diagnosis	26
BT06 (P163) Implementation of a novel direct-to-patient inflammatory teledermatology service	26
P79 A multidisciplinary expert consensus on the assessment of and support for mental health in children and young people living with skin conditions	26
BT12 A comparison of outcomes and cost-effectiveness in a teledermatology vs. a standard face-to-face 2-week wait UK model	26
641 - Pooled efficacy, patient-reported outcomes, and safety of roflumilast cream 0.15% from the INTEGUMENT-1 and INTEGUMENT-2 phase 3 trials of adults and children with atopic dermatitis	25
H15 A treatment for leprosy developed on the edge of Europe: Vincent Barry (1908–1975)	25
005 Association between prescription drugs and vaccines commonly prescribed to older people and bullous pemphigoid: a UK population-based study	24
An ontological analysis of a dataset of curated dermatological gene disease associations (G2P-Skin)	24
Expanding the SLURP1 disease spectrum: from Mal de Meleda to palmoplantar keratoderma/progressive symmetric erythrokeratoderma	24
How do dermatologists’ personal models inform a patient‐centred approach to management: a qualitative study using the example of prescribing a new treatment (Apremilast)*	24
H17 Traditional medicine: a warts-and-all tale	24
Bimekizumab safety in patients with moderate-to-severe plaque psoriasis: pooled data from up to 3 years of treatment in randomized phase III trials	24
BI08 Defining the burden of mucocutaneous disease in organ transplant recipients living with HIV: the Mucocutaneous disorders in Organ Transplant recipients living with HIV study	24
Clinical practices and educational interests of dermatologists in Caribbean countries	24
Pathways to progress: DUSP1-associated palmoplantar keratoderma in the era of precision dermatology	23
ISCL/EORTC-CLTG/USCLC recommendations for the diagnosis, staging and treatment of early-stage paediatric mycosis fungoides: a modified Delphi consensus. Part one: diagnosis and staging	23
Waning humoral and cellular immunity after COVID-19 vaccination in patients with psoriasis treated with methotrexate and biologics: a cohort study	23
DP10: A case of reactive angioendotheliomatosis with resolution following improved glycaemic control	23
Direct inhibition precedes p38 mitogen activated protein kinase-mediated uncoupling in desmosomes to reduce desmoglein 3 adhesion by pemphigus autoantibodies	23
The impact of Janus kinase 1 inhibitors on quality of life in patients with hidradenitis suppurativa	23
The future of patient-reported outcome measurement in hyperhidrosis lies in thoughtful, evidence-based implementation	23
Long-term drug survival of adalimumab, infliximab, secukinumab and ustekinumab in hidradenitis suppurativa: a Danish nationwide cohort study	23
COVID-19 vaccines and skin manifestations	23
Trichostasis spinulosa	22
Efficacy and safety of pumecitinib 3% gel in treating mild-to-moderate atopic dermatitis: a multicentre randomized double-blind parallel placebo-controlled phase IIb clinical trial	22
Gain-of-function variant in NNT causes premature diffuse familial sebaceous hyperplasia	22
514 - Tapinarof cream 1% once daily: significant efficacy in the treatment of atopic dermatitis in two pivotal phase 3 trials in adults and children down to 2 years of age	22
Molecular-guided targeted therapy with TNF inhibitor for the treatment of refractory paraneoplastic pemphigus	22
519 - Efficacy of prolonged ruxolitinib cream treatment for vitiligo among patients with limited or no initial response at 6 months	22
Sexual and gender minority inclusivity in hidradenitis suppurativa patient-reported outcome measures	22
DS17 Two cases of traumatic pseudoaneurysm of the superficial temporal artery	22
Successful treatment of severe subcorneal pustular dermatosis with the 308-nm ultraviolet B excimer laser	22
Sensitive and specific assay for the serological diagnosis of anti-p200 pemphigoid based on the recombinant laminin β4 subunit	22
Validation of a microRNA liquid biopsy assay for diagnosis and risk stratification of invasive cutaneous melanoma	22
Seeking new topical therapies in psoriasis	21
Can brepocitinib be formulated into an effective topical therapy to treat mild-to-moderate chronic plaque psoriasis?	21
Living with vulval lichen sclerosus: a qualitative interview study	21
Missing melanomas in England during the COVID-19 pandemic: 2485 fewer melanoma diagnoses in 2020 than in 2019	21
P068 A history of mycosis fungoides: from Alibert to mogamulizumab	21
High-dose, high-frequency ustekinumab therapy for patients with severe hidradenitis suppurativa	21
352 Efficacy and safety of abrocitinib in Chinese patients with moderate-to-severe atopic dermatitis: a post-hoc analysis of the JADE REGIMEN phase 3 trial	21
Consensus on the clinical management of chronic radiation dermatitis and radiation fibrosis: a Delphi survey	21
The relative contribution of the decreasing trend in tumour thickness to the 2010s increase in net survival from cutaneous malignant melanoma in Italy: a population‐based investigation*	20
Correction to: Comment on ‘Treatment of moderate-to-severe alopecia areata in preadolescent children with baricitinib’: authors’ reply	20
Real-world data on the effectiveness, safety and drug survival of dupilumab: an analysis from the TREATgermany registry	20

Greater understanding about a rare inherited skin disorder from a study of NLRP1 in two sisters with different severity of disease	20
P33 Investigating the utility and exploring biological targets of micro-wound healing compounds in 2D and 3D skin models	20
Body site-specific associations between human skin microbiome composition and psychological wellbeing	20
Parent and child experiences of skin conditions and views on mindfulness-based support	20
A review of genetic hair disorders	20
Hidradenitis suppurativa: BJD state-of-the-art review series	20
Burden of atopic dermatitis in paediatric patients: an international cross-sectional study	20
Genetic basis of a novel rare dominant form of palmoplantar keratoderma	20
Lived experiences of patients with hidradenitis suppurativa-related pain	20
P17 Pseudomonas infection causing acute painful flexural exacerbation in a child with IFAP syndrome	20
The antidiabetic medicine metformin has beneficial effects in hidradenitis suppurativa	19
Safety of long‐term treatment with risankizumab in patients with moderate‐to‐severe plaque psoriasis	19
我们如何评估前额纤维化性脱发的严重程度和治疗?	19
BG02 (P35): Alterations of forces applied under the feet in patients with epidermolysis bullosa simplex during gait	19
Creating the Scale of Alopecia Areata Distress to measure a wide range of negative emotional, social and relationship disease consequences in adults	19
便于充分了解炎症后色素沉着的模型	19
P40: Histopathological features of orofacial granulomatosis with and without underlying gut Crohn disease	19
BG12: Cicatricial junctional epidermolysis bullosa: a forgotten subtype	18
DS24: Clinical outcomes of cutaneous squamous cell carcinomas treated with Mohs micrographic surgery	18
Patient experiences of living with vulval lichen sclerosus	18
Implementing evidence-based strategies to optimize the journey of patients with hidradenitis suppurativa	18
CD03: Practical use of a limonene and linalool series	18
转移性黑色素瘤免疫治疗后患者恢复生活的经验	18
H12: Campbell De Morgan: doctor, scientist, polymath	18
Adcitmer ® 是 Merkel 细胞癌的潜在治疗方法	18
体重在 90 公斤或以上的银屑病患者获益于更为频繁的苏金单抗给药	18
P34: Exploring anaemia in hidradenitis suppurativa: a comparative study and proposal of a clinical pathway	18
PA02 (P28): Prediction of FLG genotype using human and computer‐aided phenotype extraction with random forest machine learning	18
Review of different staging systems for cutaneous squamous cell carcinoma	18
Varied skin reactions after COVID-19 vaccination	18
P55: Post‐COVID analysis of 2‐week wait face‐to‐face activity and the potential for a teledermatology service	18
A clinical trial in children and young people with severe eczema comparing methotrexate with ciclosporin	17
Insights into the biological differences in hair follicles of men with androgenetic alopecia	17
PS06 Mindfulness-based stress reduction alleviates flushing and negative emotions in rosacea: an exploratory study	17
BI24 Cutaneous pseudolymphoma secondary to pembrolizumab	17
DS13 (P141) Biodegradable temporizing matrix: a first for dermatological surgery and a valuable reconstructive adjunct	17
PD05 Chronic actinic dermatitis: a multicentre evaluation	17
P100 Critically appraised topic: is dupilumab a cause or a treatment for alopecia areata? A case series and literature review to guide discussions in clinical practice	17
DS05 Overtreatment of skin cancer: how can we ensure those treated for basal cell carcinoma receive more benefit than harm?	17
P088 Physician-assessed effectiveness, patient-reported outcomes, and safety in adult and adolescent patients with atopic dermatitis treated with dupilumab: real-world insights 1 year into the GLOBOST	17
CPC07 Lines of evidence: unravelling a case of blaschkoid Darier disease	17
DS15 Comparing the costs of monitoring vs. excision of an indeterminate naevus	17
DS28 In search of salivation? Management of parotid duct injury following Mohs micrographic surgery	17
Focusing on antigen-specific T cells	17
PD15 Ultraviolet overexposure in solar urticaria: beyond the rash	17
Editor's Choice – John Ingram – March 2024	17
‘Quantity does not make quality’: when is there a case for repeating a network meta‐analysis?	17
698 - Impact of amlitelimab (an anti-OX40 ligand antibody) on clinical outcome assessments for atopic dermatitis: results from the 52-week STREAM-AD phase 2b study in adults with moderate-to-severe at	17
BH16 Nail changes as indicators of systemic disease: a systematic review of correlations and diagnostic outcomes	17
P101 Janus kinase inhibitors in palmoplantar pustulosis: a systematic review and meta-analysis of comorbidity burden to inform a feasibility trial’s design (JAKPPPOT)	17
343 Dupilumab efficacy on itch and skin lesions in adult patients with prurigo nodularis may be observed concurrently or independently over 24 weeks: results from two phase 3 trials	16
PA32 Terra firma-forme dermatosis in siblings	16
DP22 A solitary neurofibroma masquerading as smooth muscle hamartoma: a clinicopathological challenge	16
649 - Safety of tralokinumab for the treatment of atopic dermatitis in patients with up to 4.5 years of treatment: an updated integrated analysis of eight clinical trials	16
DS21 Patients’ experience with one-stop skin cancer clinics	16
FC16 Blood mass cytometry reveals Type 1 cytokine expression in blood of patients with paradoxical eczema secondary to biologics for psoriasis	16
309 Tralokinumab demonstrated a consistent safety profile with up to 42 months of treatment in moderate-to-severe atopic dermatitis: including adverse events of special interest	16
326 Dupilumab: a comparison of infection rates across atopic dermatitis trials in adults, adolescents, children and infants	16
DP02 (P30) Declining staff numbers and increasing workload: is there a solution?	16
DE04 Large-scale virtual dermatology teaching for internal medical trainees across the UK	16
BH03 Lipoedematous scalp occurring in two female siblings: further evidence of a genetic role?	16
P15 Progressive papulonodular eruption following COVID-19 infection: a rare diagnosis and review of the literature	16
P111 An AI-assisted similarity search engine for enhanced psoriasis case identification and patient engagement	16
P53 Incidence of merkel cell carcinoma in the Republic of Ireland (1994–2019)	15
BH14 Multiple sclerosis and alopecia areata: drug-induced alopecia areata or coexisting autoimmune phenomena?	15
Diverse approaches to the diagnosis and treatment of paediatric vitiligo: a survey of paediatric dermatologists	15
703 - Efficacy and safety of ruxolitinib cream in children aged 2 to 11 years with moderate and/or more extensive atopic dermatitis: subgroup analysis from the TRuE-AD3 study	15
P45 An analysis of infantile haemangioma referrals and comparison with the infantile haemangioma European task force’s ‘infantile haemangioma referral score’	15
P156 Neoadjuvant immunotherapy for advanced melanoma: a clinical audit of pathological response and toxicity	15
428 Evaluating chronic pruritus prevalence, characteristics and effects on atopic dermatitis patients from a referral university hospital in São Paulo, Brazil: a cross-sectional study	15
HX22 Shining a light on dermatology	15
BI30 Remission of a large plantar verruca vulgaris in an immunocompromised patient postincisional punch biopsy	15
BH21 Segmented heterochromia with calibre change: an under-recognized sign of alopecia areata	15
BH19 ‘JAK in the box?’ Long-term safety concerns with oral Janus kinase inhibitors for alopecia areata	15
P046 Investigating sexual side-effects in female patients on isotretinoin via routine screening questionnaires	15
Foreword	15
O11 A patchy prognosis: identification of prognostic factors associated with progression in early-stage mycosis fungoides and first-line treatment selection	15
Officers and Committee 2024–2025	14
Dermatitis cruris pustulosa et atrophicans	14
A study looking at a possible new drug, HB0017, for the treatment of psoriasis	14
FC09 Clinical and immunomodulatory effects of mesenchymal stromal cells in multiple biologic-refractory psoriasis	14
Immunoregulatory effects of TPM203 peptide-nanoparticle therapy in pemphigus vulgaris	14
DE02 Honing in on clinician needs: a grassroots development of an educational resource for dermatologists	14
622 - Shifting the care paradigm for individuals with skin of color (SOC): a comprehensive review of care gaps and emerging initiatives in dermatology	14
Stigma in vitiligo: associated factors and severity strata of the Patient Unique Stigmatization Holistic tool in Dermatology (PUSH-D) score	14
Infectious disease among adults with allergic contact dermatitis: a propensity score-matched case–control study	13
Correction to: Microbiome characterization of skin biopsies in Spanish patients with hidradenitis suppurativa shows a decrease in D1 and H1 lineages of Cutibacterium acnes	13
PS02 (P16): Gender and sexual identity: unmet dermatological needs of LGBTQ + individuals and how dermatologists can provide better care: a qualitative analysis of a	13
Regaining adequate treatment responses in patients with psoriasis who discontinued dose reduction of adalimumab, etanercept or ustekinumab	13
Discovering skin-rejuvenating matrikines: a new frontier in basic and applied dermatology	13
O01 Inborn errors of metabolism - Solving the puzzle of prolidase deficiency	13
BI20 A fatal case of disseminated cutaneous Mycobacterium chelonae infection in an immunocompromised patient	13
Artificial daylight photodynamic therapy using methyl aminolaevulinate in a real-world setting in Germany: results from the noninterventional study ArtLight	13
P05 Pre-visit online paediatric atopic dermatitis questionnaire – a feasibility study	13
Erratum	13